Jeil Pharma Holdings Inc

Jeil Pharma Holdings Inc. is a South Korean pharmaceutical enterprise focused on the production and sale of active pharmaceutical ingredients (APIs), incrementally modified drugs (IMDs), and generic pharmaceuticals. The company's comprehensive API portfolio encompasses a variety of therapeutic areas, including antimicrobials, gastrointestinal remedies, cardiovascular medications, neuropsychiatric treatments, oncology drugs, endocrinology products, urology solutions, antivirals, and antihistamines, in addition to transdermal patch formulations. Furthermore, Jeil Pharma Holdings offers a broad selection of finished dosage forms addressing conditions such as bacterial, fungal, and viral infections; cardiovascular and endocrine disorders; neurological and gastrointestinal ailments; urological and oncological diseases. Its extensive range also features antihistamines, rheumatology, respiratory, otolaryngological, hepatic, and purgative agents. With a global presence, Jeil Pharma Holdings Inc. exports its products to approximately 40 countries, spanning regions like Southeast Asia, Central and South America, and Africa. Founded in 1959, the company's headquarters are situated in Seoul, South Korea.